Target Name: EPB41L1
NCBI ID: G2036
Other Name(s): KIAA0338 | neuronal protein 4.1 | erythrocyte membrane protein band 4.1 like 1 | DKFZp686H17242 | OTTHUMP00000030829 | OTTHUMP00000030826 | Band 4.1-like protein 1 | Erythrocyte membrane protein band 4.1 like 1, transcript variant 1 | 4.1N | EPB41L1 variant 5 | band 4.1-like protein 1 | E41L1_HUMAN | Band 4.1-like protein 1 (isoform b) | EPB41L1 variant 1 | Erythrocyte membrane protein band 4.1 like 1, transcript variant 5 | OTTHUMP00000030825 | neuron-type nonerythroid protein 4.1 | Band 4.1-like protein 1 (isoform a) | MRD11 | Neuron-type nonerythroid protein 4.1 | Neuronal protein 4.1 | OTTHUMP00000030827 | MGC11072 | Erythrocyte membrane protein band 4.1-like 1

EPB41L1: A Protein Involved in Disease Development

EPB41L1 (KIAA0338) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the E-cadherin family, which is a group of transmembrane proteins that play a role in cell-cell adhesion.

One of the unique features of EPB41L1 is its ability to interact with the protein PDGF-BB, which is a key signaling molecule in the development and maintenance of tissues. This interaction between EPB41L1 and PDGF-BB has led to the conclusion that EPB41L1 may be a drug target or biomarker for various diseases.

EPB41L1 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, studies have shown that high levels of EPB41L1 are associated with poor prognosis in patients with pancreatic cancer, and that decreased levels of EPB41L1 are associated with increased risk of developing heart disease.

In addition to its potential as a drug target or biomarker, EPB41L1 is also of interest as a potential therapeutic target for treating certain neurological disorders. For example, studies have shown that EPB41L1 is involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, targeting EPB41L1 with drugs or other therapeutic agents may be a promising approach to treating these disorders.

In conclusion, EPB41L1 is a protein that has been shown to play a role in the development and progression of various diseases. Its interaction with PDGF-BB and its association with cancer, neurodegenerative diseases, and cardiovascular diseases make it an attractive target for drug development. Further research is needed to fully understand the role of EPB41L1 in these diseases and to develop effective therapies that target this protein.

Protein Name: Erythrocyte Membrane Protein Band 4.1 Like 1

Functions: May function to confer stability and plasticity to neuronal membrane via multiple interactions, including the spectrin-actin-based cytoskeleton, integral membrane channels and membrane-associated guanylate kinases

More Common Targets

EPB41L1-AS1 | EPB41L2 | EPB41L3 | EPB41L4A | EPB41L4A-AS1 | EPB41L4A-DT | EPB41L4B | EPB41L5 | EPB42 | EPC1 | EPC2 | EPCAM | EPCAM-DT | EPDR1 | EPG5 | EPGN | EPHA1 | EPHA1-AS1 | EPHA10 | EPHA2 | EPHA2-AS1 | EPHA3 | EPHA4 | EPHA5 | EPHA5-AS1 | EPHA6 | EPHA7 | EPHA8 | EPHB1 | EPHB2 | EPHB3 | EPHB4 | EPHB6 | Ephrin Receptor | EPHX1 | EPHX2 | EPHX3 | EPHX4 | EPIC1 | EPIST | Epithelial Sodium Channel (ENaC) | EPM2A | EPM2A-DT | EPM2AIP1 | EPN1 | EPN2 | EPN3 | EPO | EPOP | EPOR | Epoxide Hydrolase | EPPIN | EPPK1 | EPRS1 | EPS15 | EPS15L1 | EPS8 | EPS8L1 | EPS8L2 | EPS8L3 | EPSTI1 | EPX | EPYC | EQTN | ER Membrane Protein Complex | ERAL1 | ERAP1 | ERAP2 | ERAS | ERBB2 | ERBB3 | ERBB4 | ERBIN | ERC1 | ERC2 | ERC2-IT1 | ERCC1 | ERCC2 | ERCC3 | ERCC4 | ERCC5 | ERCC6 | ERCC6L | ERCC6L2 | ERCC6L2-AS1 | ERCC8 | EREG | ERF | ERFE | ERG | ERG28 | ERGIC1 | ERGIC2 | ERGIC3 | ERH | ERHP1 | ERI1 | ERI2 | ERI3 | ERICH1